Demyelinating Diseases Therapeutics Market Overview
Demyelinating Diseases Therapeutics Market Size is estimated to reach $1.3 billion by 2027 and is poised to grow at a CAGR of 10.7% over the forecast period of 2022-2027. A demyelinating disease is any condition that causes damage to the protective covering myelin sheath. Demyelinating illnesses are caused by immunological responses, viral agents and genetic abnormalities. According to a Springer report published in August 2019, 1 in 500 people suffer from the demyelinating disease. Clinically isolated syndrome, demyelinating disorders, multiple sclerosis, transverse myelitis, Parkinson’s and Guillain Barre are some diseases that come under Demyelinating diseases. The use of glatiramer acetate, immunomodulators and immunosuppressants is considered an effective treatment for demyelinating diseases. Also, remyelination therapy is found effective for treating demyelinating disease. This is a life-threatening disease that leads to paralysis, responsible disability and trouble breathing. Such a threat of demyelinating disease to mankind surge demand for new innovative therapeutics and fuel the growth of demyelinating disease therapeutics industry over the forecast period 2022-2027.
Demyelinating Diseases Therapeutics Market Report Coverage
The report: “Demyelinating Diseases Therapeutics Market Forecast (2022-2027)" by Industry ARC, covers an in-depth analysis of the following segments in the Demyelinating Diseases Therapeutics Market.
by Drug Type: Corticosteroids,
Immunoglobulin and Others.
by End-users: Hospitals, Ambulatory Surgical Centers, Specialised Clinics and Others.
by Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others.
by Geography: North America (the US, Canada and Mexico), Europe (Germany, the UK, France, Italy, Spain, Russia and the Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia and New Zealand and the Rest of Asia Pacific), South America (Brazil, Argentina, Chile, Colombia and the Rest of South America) and Rest of the World (the Middle East and Africa).
- Geographically, North America held a dominant market share in the year 2021, owing to the high investment in healthcare propelling the growth of the Demyelinating Diseases Therapeutics Market Size.
- The Demyelinating Diseases Therapeutics Market is predicted to increase due to the growing geriatric population and increasing prevalence of auto-immune diseases.
- However, the high cost of research may limit Demyelinating Diseases Therapeutics Industry growth over the forecast period 2022-2027.
- A detailed analysis of strengths, weaknesses, opportunities and threats would be provided in the Demyelinating Diseases Therapeutics Market Report.
Demyelinating Diseases Therapeutics Market: Market Share (%) by region, 2021
Demyelinating Diseases Therapeutics Market Segment Analysis - by Drug Type
Demyelinating Diseases Therapeutics Market based on drug type can be further segmented into Corticosteroids, Immunoglobulin and Others. The Corticosteroids segment held a dominant market share in the year 2021. This is owing to the effectiveness of corticosteroids such as prednisone and prednisolone on demyelinating diseases. The study found that the use of corticosteroids leads to improvement in 60% of patients and remission in 61% of treatment respondents. The growing effectiveness of corticosteroids surges the growth of the demyelinating disease therapeutics market share.
However, Immunoglobulins are estimated to grow with the fastest CAGR of 11.5% over the forecast period 2022-2027. This is owing to the injectable nature of immunoglobulins. According to clinical trials, intravenous immunoglobulin is an effective alternative to standard therapies for the disease. Such use of immunosuppressant drugs for the treatment of demyelinating disease fuel the growth of the Demyelinating Diseases Therapeutics Market Share.
Demyelinating Diseases Therapeutics Market Segment Analysis - by Distribution Channels
Demyelinating Diseases Therapeutics Market based on the distribution channels can be further segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and others. The hospital pharmacy segment held a dominant Demyelinating Diseases Therapeutics market share in the year 2021. This is the result of increasing hospital admission of patients with disabilities. Such growing hospitalization for demyelinating diseases creates demand for various treatments such as remyelination. Furthermore, the use of drugs like glatiramer acetate, immunomodulators, immunosuppressants and other therapeutics from hospital pharmacies drives the growth of the Demyelinating Disease Therapeutics Market Share. However, the Online Pharmacies segment is estimated to grow with the fastest CAGR of 11.2% over the forecast period 2022-2027. This is owing to the rapid growth of technology and the availability of drugs in online pharmacies. Such popularisation of online pharmacies and growing demand for various drugs like glatiramer acetate, immunomodulators, immunosuppressants and other therapeutics from online pharmacies fuel the growth of the Demyelinating Diseases Therapeutics Market Share over the forecast period 2022-2027.
Demyelinating Diseases Therapeutics Market Segment Analysis - by Geography
North America held a dominant market share of 36% in 2021. This is due to growing cases of Demyelinating Disease in this region. According to the Multiple Sclerosis Association of America (MSAA), nearly 1 million people are living with multiple sclerosis in the United States. Such growing cases of demyelinating diseases surge demand for various therapeutics such as immunomodulators, glatiramer acetate which is used to treat multiple sclerosis, immunosuppressants and other treatments like remyelination. Such growing demand for various therapeutics drives the growth of the Demyelinating Diseases Therapeutics market size. Furthermore, Europe is estimated to grow with the fastest CAGR over the forecast period 2022-2027. This is because of the growing prevalence of various demyelinating diseases such as Neuromyelitis in Europe. Such a growing need for the treatment of demyelinating diseases and new innovative treatments available in the market fuel growth of the Demyelinating Diseases Therapeutics market size over the forecast period 2022-2027.
Demyelinating Diseases Therapeutics Market Drivers
Growing Prevalence of Rare Diseases:
The rare diseases are increasing in the world. Currently, there are 3,585 rare diseases in the world. According to Rare Genomics Institutes, the rare disease affects about 200,000 Americans and 12,000 European people at any given time. Such the growing prevalence of rare diseases drives the growth of the Demyelinating Disease Therapeutics Industry over the forecast period 2022-2027.
Unavailability of Proper Treatment:
The availability and access to medicines are important to reduce morbidity and mortality associated with rare diseases. Also, the correct diagnosis is important to identify and cure proper diseases. Less than 5% of the 7,000-8,000 rare diseases exist with treatments that can be used to treat them. Less than 1 in 10 individuals receive treatment specifically for their disease and over 95% of rare diseases have no approved treatments as per the report published by National Policy for Rare Diseases in 2021. Such conditions increase demand for new therapeutics and drive the growth of the Demyelinating Diseases Therapeutics Industry over the forecast period 2022-2027.
Demyelinating Diseases Therapeutics Market Challenge
High Cost for Diagnosis & Treatment:
The cost for diagnosis and treatment of demyelinating disease is very high. According to a report by Institute for Clinical and Economic Review (ICER), In 2019, the average annual cost of a rare disease treatment per treated patient was $32,000, with treatments ranging from $6,000 to $500,000 per year. Such high diagnosis costs and high cost of treatment may limit the Demyelinating Diseases Therapeutics Industry growth over the forecast period 2022-2027.
Demyelinating Diseases Therapeutics Market Industry Outlook
Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Demyelinating Diseases Therapeutics industry. The top 10 companies in the Demyelinating Diseases Therapeutics Market are:
1. Teva Pharmaceutical Industries Ltd
2. Sanofi S.A.
3. Novartis AG.
4. Merck & Co., Inc.
5. F. Hoffmann-La Roche Ltd.
6. Pfizer, Inc.
7. Biogen Inc.
8. Bayer AG
9. Actelion Pharmaceuticals Ltd.
10. GlaxoSmithKline plc.
11. Opexa Therapeutics, Inc.
- In March 2022, Teva Pharmaceutical Industries Ltd announced the launch of the first generic version of Revlimid (lenalidomide capsules), in 5mg, 10mg, 15mg and 25mg strengths, in the United States. Teva’s Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma in combination with the medicine dexamethasone.
- In February 2022, Sanofi announced the completion of its acquisition of Amunix Pharmaceuticals, Inc., adding a promising pipeline of T-cell engagers and cytokine therapies.
- In September 2021, Novartis announced the acquisition of Arctos Medical, adding a pre-clinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its ophthalmology portfolio.